Dipipanone 10mg / Cyclizine 30mg tablets
Requires a prescription from a doctor or prescriber
Strict controls: safe custody, register required
Legal requirements and restrictions
These are medicines with high potential for misuse but with accepted medical uses. Subject to the strictest controls.
Legal requirements
- Must be stored in a locked controlled drugs cabinet
- Pharmacy must keep a controlled drugs register
- Prescriptions valid for 28 days only
- Prescriptions must include specific details (dose, form, strength, total quantity)
- Cannot be emergency supplied by pharmacists
Other medicines in this category
Morphine, Oxycodone, Fentanyl, Methylphenidate (Ritalin), Amphetamines
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
5 branded products available
MHRA licensed products
View all licensed products for Dipipanone + Cyclizine on the MHRA register
Dipipanone 10mg / Cyclizine 30mg tablets
Dipipanone 10mg / Cyclizine 30mg tablets
Dipipanone 10mg / Cyclizine 30mg tablets
Dipipanone 10mg / Cyclizine 30mg tablets
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 5 · Randomised trials: 1 · 1958–2026
Showing the 50 most relevant studies, sorted by most relevant.
Shahmeer Hamid, Badr Bahaj, Zain U Sajhad
Cureus, 2026
Postoperative nausea and vomiting (PONV) are frequent complications following general anaesthesia, demanding effective and cost-efficient prophylactic strategies. Therefore, this study aimed to assess the comparative efficacy and safety of ondansetron versus cyclizine for PONV prophylaxis in adult surgical patients by adopting a meta-analysis research approach. The Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines were adopted in selecting and screening the studies. A computer-based search of the EMBASE, MEDLINE, CENTRAL, and CINAHL databases was carried out using the last search up to November 2025. The risk of bias of the included randomised controlled trials (RCTs) was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool. A sensitivity analysis was performed to assess robustness, and the certainty of evidence was evaluated using Grading of Recommendations Assessment, Development and Evaluation (GRADE). All statistical analyses were performed using MetaAnalysisOnline software. Four RCTs involving 433 adult surgical patients were included. Pooled analysis showed that ondansetron did not significantly reduce the incidence of any PONV compared to cyclizine (odds ratio: 0.74, 95% CI: 0.34 to 1.61, p=0.45). Sensitivity analysis confirmed this finding across surgical subtypes. Additionally, there were no significant differences in the incidence of postoperative vomiting (odds ratio: 1.11, 95% CI: 0.61 to 2.02, p=0.74) or the requirement for rescue antiemetics (odds ratio: 1.83, 95% CI: 0.95 to 3.52, p=0.07). However, moderate heterogeneity was observed (I2=68%) for the primary outcome, and cyclizine was associated with a statistically significant, though clinically small, delay in time to eye opening (mean difference: 2.00 min, p<0.001). The overall certainty of evidence was graded as low to very low. Low-certainty evidence indicates that cyclizine is a reasonable approach to preventing PONV, offering comparable efficacy to ondansetron without prolonging hospital discharge times. Due to its cost-effectiveness and potential specific benefit in diagnostic laparoscopy, it might be useful for ambulatory surgical centres aiming to optimize value-based care. However, the efficacy of cyclizine within modern multimodal protocols has not been consistently determined by these monotherapy trials, and long-term assessments of combined antiemetic strategies need to be evaluated.
Abstract licence: CC BY
Philip Whitehurst
http://isrctn.org/>, 2013
M. Clubley, C. Bye, T. Henson, et al.
British journal of clinical pharmacology, 1979
Kasper Petersen, P. Hjorth
Ugeskrift for laeger, 2018
S. Nortcliffe, J. Shah, D. Buggy
British journal of anaesthesia, 2003
S. Borukhova, T. Noël, V. Hessel
ChemSusChem, 2016
M. S. Afanamol, A. Deepika Dinesh, K. Shifa Ali, et al.
In Silico Pharmacology, 2023
F. Bailey, A. Davies
Palliative Medicine, 2008
Yin-Che Lu, Chen-Yu Chiang, Yu-Wei Hsu, et al.
Environmental Toxicology, 2024
Hao Wu, Chen-Yu Chiang, Wen-Ying Chen, et al.
Environmental Toxicology, 2023
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.